2.97
Adverum Biotechnologies Inc stock is traded at $2.97, with a volume of 128.00K.
It is up +1.37% in the last 24 hours and up +11.24% over the past month.
Adverum Biotechnologies Inc is a clinical-stage company that aims to establish gene therapy as a new standard of care for prevalent ocular diseases. It develops gene therapy product candidates intended to provide durable efficacy by inducing sustained expression of a therapeutic protein. Its product candidate, ixoberogene soroparvovec (Ixo-vec), is a single, in-office intravitreal (IVT) injection gene therapy product designed to deliver long-term durable therapeutic levels of aflibercept associated with a robust, sustained treatment response, reducing the treatment burden and fluctuations in macular fluid associated with bolus anti-vascular endothelial growth factor (VEGF) IVT injections.
See More
Previous Close:
$2.93
Open:
$2.95
24h Volume:
128.00K
Relative Volume:
0.63
Market Cap:
$62.32M
Revenue:
-
Net Income/Loss:
$-94.11M
P/E Ratio:
-0.4942
EPS:
-6.01
Net Cash Flow:
$-86.06M
1W Performance:
+3.85%
1M Performance:
+11.24%
6M Performance:
-24.62%
1Y Performance:
-57.87%
Adverum Biotechnologies Inc Stock (ADVM) Company Profile
Name
Adverum Biotechnologies Inc
Sector
Industry
Phone
(650) 649-1004
Address
100 CARDINAL WAY, REDWOOD CITY, CA
Compare ADVM with other stocks
Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
---|---|---|---|---|---|---|
![]()
ADVM
Adverum Biotechnologies Inc
|
2.97 | 61.48M | 0 | -94.11M | -86.06M | -6.01 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
395.12 | 99.96B | 11.39B | 3.64B | 3.50B | 13.99 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
589.48 | 60.83B | 14.21B | 4.46B | 3.56B | 39.68 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
454.38 | 59.89B | 2.46B | -319.09M | -52.09M | -2.47 |
![]()
ARGX
Argen X Se Adr
|
660.00 | 40.47B | 3.06B | 1.28B | 447.35M | 21.30 |
![]()
ONC
Beone Medicines Ltd Adr
|
313.67 | 37.96B | 3.81B | -644.79M | -669.77M | -6.24 |
Adverum Biotechnologies Inc Stock (ADVM) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Jun-25-24 | Initiated | Oppenheimer | Outperform |
Apr-30-24 | Initiated | H.C. Wainwright | Buy |
Jul-07-22 | Upgrade | Truist | Hold → Buy |
Jul-23-21 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
May-03-21 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
Apr-29-21 | Downgrade | Chardan Capital Markets | Buy → Neutral |
Apr-29-21 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
Apr-29-21 | Downgrade | Truist | Buy → Hold |
Dec-16-20 | Initiated | UBS | Neutral |
Nov-12-20 | Upgrade | Raymond James | Underperform → Mkt Perform |
Jun-26-20 | Downgrade | Raymond James | Mkt Perform → Underperform |
May-13-20 | Initiated | RBC Capital Mkts | Outperform |
May-05-20 | Upgrade | SunTrust | Hold → Buy |
Apr-28-20 | Initiated | Goldman | Buy |
Mar-16-20 | Initiated | SVB Leerink | Outperform |
Feb-10-20 | Upgrade | Cantor Fitzgerald | Neutral → Overweight |
Feb-10-20 | Upgrade | Chardan Capital Markets | Neutral → Buy |
Oct-15-19 | Reiterated | Chardan Capital Markets | Neutral |
Sep-13-19 | Reiterated | Chardan Capital Markets | Neutral |
Jun-14-19 | Resumed | Raymond James | Mkt Perform |
Nov-02-18 | Downgrade | Raymond James | Outperform → Mkt Perform |
Nov-02-18 | Downgrade | SunTrust | Buy → Hold |
Sep-21-18 | Initiated | Cantor Fitzgerald | Overweight |
Aug-30-18 | Initiated | SunTrust | Buy |
Feb-15-18 | Resumed | Piper Jaffray | Overweight |
Oct-12-17 | Initiated | Raymond James | Outperform |
View All
Adverum Biotechnologies Inc Stock (ADVM) Latest News
Chartists Watching For Breakout in Adverum Biotechnologies Inc.July 2025 Action & Daily Stock Trend Watchlist - newsyoung.net
Global Ophthalmology Drugs Market to Reach USD 26.28 Billion by 2030 | MarketsandMarkets™ - GlobeNewswire Inc.
Real time alert setup for Adverum Biotechnologies Inc. performanceStock Surge & Reliable Momentum Entry Alerts - Newser
Full technical analysis of Adverum Biotechnologies Inc. stockJuly 2025 Selloffs & Free High Return Stock Watch Alerts - Newser
Technical analysis overview for Adverum Biotechnologies Inc. stockWeekly Stock Summary & Smart Money Movement Alerts - Newser
Reversal indicators forming on Adverum Biotechnologies Inc. stock2025 Volatility Report & Fast Entry High Yield Tips - Newser
Chardan Capital Keeps Buy Rating for ADVM with $33 Price Target - AInvest
Adverum Biotechnologies (NASDAQ:ADVM) Receives “Buy” Rating from Chardan Capital - Defense World
What makes Adverum Biotechnologies Inc. stock price move sharply2025 Earnings Surprises & Stock Portfolio Risk Control - Newser
How to build a dashboard for Adverum Biotechnologies Inc. stockGDP Growth & Verified Trade Idea Suggestions - Newser
Chardan Capital Keeps Buy Rating on Adverum, Raises PT to $33 - AInvest
Using data tools to time your Adverum Biotechnologies Inc. exit2025 Geopolitical Influence & Low Risk Entry Point Tips - Newser
Adverum Biotechnologies shares rise 6.88% premarket after reporting a loss of $49.2 million in Q2 2025. - AInvest
Adverum Biotechnologies: Q2 Earnings Snapshot - Greenwich Time
Promising Outlook for Adverum Biotechnologies’ Ixo-vec in Wet AMD Treatment: Buy Rating Affirmed - TipRanks
How high can Adverum Biotechnologies Inc. stock price go in 20252025 Volatility Report & Long-Term Growth Stock Strategies - Newser
Adverum Biotechnologies Faces Financial Hurdles Amid Gene Therapy Development - AInvest
Adverum Biotechnologies Faces Financial Challenges Amid Gene Therapy Development - TipRanks
Adverum Biotechnologies Reports Second Quarter 2025 Financial Results and Provides Pipeline Highlights - GlobeNewswire
Adverum Biotechnologies shares fall 8.91% after-hours after reporting a larger-than-expected Q2 loss. - AInvest
Adverum Biotechnologies shares rise 4.86% after-hours despite reporting a $49.2 million loss in Q2. - AInvest
Adverum Biotechnologies Q2: ARTEMIS Phase 3 enrollment exceeds expectations. - AInvest
Adverum Biotechnologies Q2 GAAP EPS Misses Expectations, Cash Holdings Down to $44.4M - AInvest
Adverum Biotechnologies Reports Q2 2025 Financial Results, Exceeds ARTEMIS Enrollment Expectations, Announces $10M Private Placement with Frazier Life Sciences. - AInvest
Adverum Biotechnologies, Inc. SEC 10-Q Report - TradingView
Adverum Biotechnologies reports Q2 EPS ($2.34), consensus ($2.28) - TipRanks
Adverum Biotechnologies Q2: ARTEMIS Phase 3 Enrollment Exceeds Expectations, $10mln Private Placement - AInvest
Adverum's One-and-Done Eye Treatment Attracts Record Trial Enrollment as 50% of Specialists Back Gene Therapy - Stock Titan
Technical signs of recovery in Adverum Biotechnologies Inc.3-Year Equity Summary With Setup Insights - Newser
Published on: 2025-08-11 03:29:27 - Newser
Is Adverum Biotechnologies Inc. stock bottoming outReal Trader Watchlist with Entry Targets - Newser
What to do if you’re stuck in Adverum Biotechnologies Inc.High Confidence Strategy with Trend Alignment - Newser
Adverum Biotechnologies Inc. stock prediction for this weekChart Driven Opportunity Scanner with Alerts - Newser
Is Adverum Biotechnologies Inc. a candidate for recovery playMarket Opportunity Tracker for Swing Traders - Newser
Adverum Biotechnologies Inc expected to post a loss of $2.25 a shareEarnings Preview - TradingView
Adverum Biotechnologies shares fall 2.38% intraday after executives to participate in H.C. Wainwright 5th Annual Ophthalmology Virtual Conference. - AInvest
Adverum Biotechnologies to Participate in the H.C. Wainwright 5th Annual Ophthalmology Virtual Conference - GlobeNewswire
Adverum Leadership to Share Latest Ophthalmology Insights at H.C. Wainwright Conference - Stock Titan
Adverum Biotechnologies Inc Stock (ADVM) Financials Data
Revenue
Net Income
Cash Flow
EPS
Adverum Biotechnologies Inc Stock (ADVM) Insider Trading
Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
---|---|---|---|---|---|---|---|
Seyedkazemi Setareh | CHIEF DEVELOPMENT OFFICER |
May 15 '25 |
Sale |
2.00 |
924 |
1,848 |
13,768 |
Fischer Laurent | CEO, PRESIDENT AND DIRECTOR |
May 15 '25 |
Sale |
2.00 |
9,126 |
18,252 |
87,488 |
Leonard Braden Michael | 10% Owner |
Mar 26 '25 |
Buy |
5.04 |
20,407 |
102,841 |
125,207 |
Leonard Braden Michael | 10% Owner |
Mar 27 '25 |
Buy |
5.19 |
16,593 |
86,089 |
141,800 |
Leonard Braden Michael | 10% Owner |
Apr 22 '25 |
Buy |
3.00 |
300,000 |
900,000 |
3,057,526 |
Leonard Braden Michael | 10% Owner |
Apr 23 '25 |
Buy |
2.98 |
50,000 |
148,950 |
191,800 |
Leonard Braden Michael | 10% Owner |
Mar 31 '25 |
Buy |
4.38 |
19,566 |
85,668 |
2,742,317 |
Leonard Braden Michael | 10% Owner |
Apr 02 '25 |
Buy |
4.04 |
15,209 |
61,408 |
2,757,526 |
Leonard Braden Michael | 10% Owner |
Mar 26 '25 |
Buy |
5.04 |
20,407 |
102,841 |
125,207 |
Leonard Braden Michael | 10% Owner |
Mar 18 '25 |
Buy |
4.69 |
62,341 |
292,418 |
2,667,161 |
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):